<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The discovery of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> has made arguably the biggest contribution to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> medicine, providing the basis for the chemotherapy treatment of many <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to well-documented toxicities such as neurotoxicity, <z:chebi fb="2" ids="27899">cisplatin</z:chebi>-induced vascular toxicity is becoming an increasing concern, with some authors describing it in up to 12% of patients </plain></SENT>
<SENT sid="2" pm="."><plain>Given the efficacy of <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, vascular toxicity represents a significant survivorship issue </plain></SENT>
<SENT sid="3" pm="."><plain>We describe different manifestations of <z:chebi fb="2" ids="27899">cisplatin</z:chebi>-associated <z:mp ids='MP_0005048'>thrombosis</z:mp> and its putative pathophysiology </plain></SENT>
</text></document>